Relapse of Thrombotic Thrombocytopenic Purpura: Is It a Continuum of Disease?

ABSTRACT

The recurrence of thrombotic thrombocytopenic purpura (TTP) in 20 to 50% of patients who survive their initial episode, is not only a challenge to manage clinically, but brings to light our lack of understanding of the underlying pathophysiology. Recurrence may occur close to apparent hematologic remission or remotely, months later. Given that surveillance of TTP relies on surrogate measures such as hematologic recovery, normalization of serum lactate dehydrogenase (LDH) and resolution of clinical signs, it is plausible that some recurrences are actually a continuum of disease. Standardizing definitions for remission, exacerbation, and relapse are important for consistency of patient management and interpreting the medical literature. When TTP recurs, several adjuncts to therapeutic plasma exchange (TPE) have been used, including splenectomy, vincristine, and rituximab. Although it would seem intuitive that more severe disease would predict a greater likelihood of relapse, the degree of thrombocytopenia at presentation, the persistence of schistocytosis at discontinuation of TPE, the elevation of LDH, and the length of time to attain clinical remission are not reliable indicators of the clinical outcome of any individual TTP patient. Measurement of ADAMTS13 activity and its inhibitor offer new promise for prognostic and pathophysiologic significance; however, more extensive scientific investigation is needed.

Thrombotic thrombocytopenic purpura (TTP) - prognostic factors - relapse - adjunct therapy

REFERENCES

• 1 Sadler J E, Moake J L, Miyata T, George J N. Recent advances in thrombotic thrombocytopenic purpura.  Hematology (Am Soc Hematol Educ Program). 2004;  1 407-423
• 2 George J N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Blood. 2000;  96 1223-1229
• 3 Shumak K H, Rock G A, Nair R C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group.  Ann Intern Med. 1995;  122 569-572
• 4 Bandarenko N, Brecher M E. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.  J Clin Apheresis. 1998;  13 133-141
• 5 Egan J A, Hay S N, Brecher M E. Frequency and significance of schistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy.  J Clin Apheresis. 2004;  19 165-167
• 6 Committee AET .Guidelines for Therapeutic Hemapheresis. Bethesda, MD; American Association of Blood Banks 1993
• 7 Gilcher R O, Strauss R G, Ciavarella D et al.. Management of renal disorders.  J Clin Apheresis. 1993;  8 258-269
• 8 Downes K A, Yomtovian R, Tsai H M, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident.  J Clin Apheresis. 2004;  19 86-89
• 9 Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 1999;  81 8-13
• 10 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
• 11 Rock G, Anderson D, Clark W et al.. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet.  Br J Haematol. 2005;  129 79-86
• 12 Rock G. Thrombotic thrombocytopenic purpura: Current therapies and diagnostic tools.  J Clin Apheresis. 2005;  20 9 , (abst)
• 13 George J N, Vesely S K, Terrell D R. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.  Semin Hematol. 2004;  41 60-67
• 14 Rock G, Shumak K H, Sutton D M, Buskard N A, Nair R C. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group.  Br J Haematol. 1996;  94 383-386
• 15 Lakey M A, Boctor F N, Knight C W, Marques M B. VWF-cleaving protease activity and inhibitor levels do not predict duration of treatment in TTP and HUS.  J Clin Apheresis. 2005;  20 7 , (abst)
• 16 Egan J A, Hay S N, Millward P A, Bandarenko N, Brecher M E. Effect of discontinuation of plasma exchange in pseudo-refractory thrombotic thrombocytopenic purpura patients.  J Clin Apheresis. 2005;  20 8 , (abst)
• 17 Hay S H, Egan J A, Millward P A. Declining platelet counts in TTP patients receiving daily plasma exchange: frequency and Outcome.  J Clin Apheresis. 2005;  20 10 , (abst)
• 18 Tsai H M, Rice L, Sarode R, Chow T W, Moake J L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.  Ann Intern Med. 2000;  132 794-799
• 19 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 20 Reutter J C, Sanders K F, Brecher M E, Jones H G, Bandarenko N. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura.  J Clin Apheresis. 2001;  16 134-138
• 21 Mokrzycki M H, Kaplan A A. Therapeutic plasma exchange: complications and management.  Am J Kidney Dis. 1994;  23 817-827
• 22 Sutton D M, Nair R C, Rock G. Complications of plasma exchange.  Transfusion. 1989;  29 124-127
• 23 McLeod B C, Sniecinski I, Ciavarella D et al.. Frequency of immediate adverse effects associated with therapeutic apheresis.  Transfusion. 1999;  39 282-288
• 24 Schneider P A, Rayner A A, Linker C A, Schuman M A, Liu E T, Hohn D C. The role of splenectomy in multimodality treatment of thrombotic thrombocytopenic purpura.  Ann Surg. 1985;  202 318-322
• 25 Veltman G A, Brand A, Leeksma O C, ten Bosch G J, van Krieken J H, Briet E. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura.  Ann Hematol. 1995;  70 231-236
• 26 Winslow G A, Nelson E W. Thrombotic thrombocytopenic purpura: indications for and results of splenectomy.  Am J Surg. 1995;  170 558-561
• 27 Aqui N A, Stein S H, Konkle B A, Abrams C S, Strobl F J. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.  J Clin Apheresis. 2003;  18 51-54
• 28 Islam M N, Iskander M N. Microtubulin binding sites as target for developing anticancer agents.  Mini Rev Med Chem. 2004;  4 1077-1104
• 29 Burns E R, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.  Blood. 1982;  60 1030-1037
• 30 Gutterman L A. Treatment of TTP and HUS: the role of vincristine. In: Kaplan BS, Trompeter RS, Moake JL Hemolyic Uremic Syndrome and Thrombotic Thrombocytopenic Purpua. New York; Dekker 1992: 513-530
• 31 [No author] . Treatment for thrombotic thrombocytopenic purpura: plasma, vincristine, hemodialysis and exchange transfusions.  N Engl J Med. 1978;  298 971-972
• 32 Ziman A, Mitri M, Klapper E, Pepkowitz S H, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature.  Transfusion. 2005;  45 41-49
• 33 Dervenoulas J, Tsirigotis P, Bollas G et al.. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases.  Acta Haematol. 2001;  105 204-208
• 34 Castaman G, Rodeghiero F, Ruggeri M, di Bona E, Dini E. Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura.  Haematologica. 1991;  76 511-512
• 35 Kondo H, Imamura T. Effects of intravenous immunoglobulin in a patient with intermittent thrombotic thrombocytopenic purpura.  Br J Haematol. 2000;  108 880-882
• 36 Chambers S A, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.  Lupus. 2005;  14 210-214
• 37 Fakhouri F, Teixeira L, Delarue R, Grunfeld J P, Veyradier A. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide.  Ann Intern Med. 2004;  140 314-315
• 38 Fakhouri F, Vernant J P, Veyradier A et al.. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13 deficient-thrombotic thrombocytopenic purpura: a study of 11 cases.  Blood. 2005;  106 1932-1937
• 39 Chemnitz J, Draube A, Scheid C et al.. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.  Am J Hematol. 2002;  71 105-108
• 40 Maloney D G. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.  Semin Oncol. 2005;  32(1 suppl 1) S19-S26
• 41 Ahmad A, Aggarwal A, Sharma D et al.. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).  Am J Hematol. 2004;  77 171-176
• 42 Gutterman L A, Kloster B, Tsai H M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura.  Blood Cells Mol Dis. 2002;  28 385-391
• 43 Reddy P S, Deauna-Limayo D, Cook J D et al.. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura.  Ann Hematol. 2005;  84 232-235
• 44 Sallah S, Husain A, Wan J Y, Nguyen N P. Rituximab in patients with refractory thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2004;  2 834-836
• 45 Stein G Y, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.  Int J Hematol. 2004;  80 94-96
• 46 Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H M. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.  Br J Haematol. 2004;  124 787-795
• 47 Zheng X, Pallera A M, Goodnough L T, Sadler J E, Blinder M A. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.  Ann Intern Med. 2003;  138 105-108
• 48 Galbusera M, Bresin E, Noris M et al.. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.  Blood. 2005;  106 925-928
• 49 Bandarenko N, Stagg K F, Hay S N, Brecher M E. Cardiogenic shock complicates successful treatment of refractory TTP with rituximab.  Transfusion. 2004;  4(9S) 44A , (abst)
• 50 Silverman G J, Goodyear C S, Siegel D L. On the mechanism of staphylococcal protein A immunomodulation.  Transfusion. 2005;  45 274-280
• 51 Nand S, Molokie R. Therapeutic plasmapheresis and protein A immunoadsorption in malignancy: a brief review.  J Clin Apheresis. 1990;  5 206-212
• 52 Gaddis T G, Guthrie Jr T H, Drew M J, Sahud M, Howe R B, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption.  Am J Hematol. 1997;  55 55-58
• 53 Drew M J. Resolution of refractory, classic thrombotic thrombocytopenic purpura after staphylococcal protein A immunoadsorption.  Transfusion. 1994;  34 536-538
• 54 Musio F, Bohen E M, Yuan C M, Welch P G. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus.  Semin Arthritis Rheum. 1998;  28 1-19
• 55 Creager A J, Brecher M E, Bandarenko N. Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection.  Transfusion. 1998;  38 419-423
• 56 Tarantolo S R, Landmark J D, Iwen P C, Kessinger A, Chan W C, Hinrichs S H. Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura.  Lancet. 1997;  350 1602
• 57 Vesely S K, Li X, McMinn J R, Terrell D R, George J N. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Transfusion. 2004;  44 1149-1158
• 58 Kojouri K, Vesely S K, George J N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.  Ann Intern Med. 2001;  135 1047-1051
• 59 Bennett C L, Davidson C J, Raisch D W, Weinberg P D, Bennett R H, Feldman M D. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.  Arch Intern Med. 1999;  159 2524-2528
• 60 Zakarija A, Bandarenko N, Pandey D K et al.. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.  Stroke. 2004;  35 533-537
• 61 Dlott J S, Danielson C F, Blue-Hnidy D E, McCarthy L J. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.  Ther Apher Dial. 2004;  8 102-111
• 62 Egan J A, Bandarenko N, Hay S N et al.. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura.  J Clin Apheresis. 2004;  19 125-129
• 63 Vesely S K, George J N, Lammle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 64 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.  Best Pract Res Clin Haematol. 2001;  14 437-454